Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Enterprise Value: 2018-2025

Historic Enterprise Value for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $265.1 million.

  • Arcturus Therapeutics Holdings' Enterprise Value fell 20.98% to $265.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$533.8 million, marking a year-over-year increase of 20.58%. This contributed to the annual value of $167.6 million for FY2024, which is 66.04% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Enterprise Value stood at $265.1 million, which was up 161.51% from $101.4 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Enterprise Value ranged from a high of $618.5 million in Q1 2021 and a low of $31.8 million during Q1 2025.
  • Its 3-year average for Enterprise Value is $310.5 million, with a median of $335.5 million in 2024.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Enterprise Value spiked by 759.56% in 2023, and later tumbled by 94.39% in 2025.
  • Quarterly analysis of 5 years shows Arcturus Therapeutics Holdings' Enterprise Value stood at $605.1 million in 2021, then tumbled by 90.51% to $57.4 million in 2022, then spiked by 759.56% to $493.7 million in 2023, then tumbled by 66.04% to $167.6 million in 2024, then declined by 20.98% to $265.1 million in 2025.
  • Its last three reported values are $265.1 million in Q3 2025, $101.4 million for Q2 2025, and $31.8 million during Q1 2025.